Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome

被引：2
|
作者：
De, Surya K. [1 ,2 ]
机构：
[1] Conju Probe, San Diego, CA 92121 USA
[2] Bharath Univ, Dept Chem, Chennai, Tamil Nadu, India
来源：
FRONTIERS IN PHARMACOLOGY | 2024年 / 15卷
关键词：
idelalisib; duvelisib; copanlisib; alpelisib; leniolisib; phosphatidylinositol; 3-kinase; PI3K/AKT SIGNALING PATHWAY; PI3K-DELTA; DISCOVERY;
D O I：
10.3389/fphar.2024.1337436
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
(Figure presented.) Copyright © 2024 De.
引用
收藏
页数：7
相关论文
共 50 条
  • [1] Approach to Identification of Patients with Activated Phosphoinositide-3 Kinase Delta Syndrome (APDS)
    Suez, Daniel
    Wasserman, Richard
    Darter, Amy
    Perez, Elena
    Jacobs, Joshua
    Siri, Dareen
    Patterson, David
    Offenberger, Jacob
    Lumry, William
    Scarupa, Mark
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB81 - AB81
  • [2] LENIOLISIB EFFECT ON RESPONSE RATES FOR SELECT OUTCOMES IN ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS)
    Harrington, A.
    Chinn, I.
    Fuleihan, R.
    Simpson, S.
    Bradt, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S60 - S60
  • [3] Leniolisib: a drug providing a promising avenue for the treatment of activated phosphoinositide 3-kinase δ syndrome (APDS)
    Ali, Anoshia
    Qureshi, Amsal
    Shigri, Anum Fatima
    Alvi, Areesha Moiz
    Malikzai, Abdullah
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (07): : 3812 - 3813
  • [4] ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME: A CASE SERIES
    Sheikh, J.
    Kaplan, M.
    Samant, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S103 - S103
  • [5] Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome
    Condliffe, Alison M.
    Chandra, Anita
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [6] CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib
    De Buck, Stefan
    Kucher, Klaus
    Hara, Hisanori
    Gray, Cathy
    Woessner, Ralph
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (08) : 394 - 402
  • [7] CLONING AND CHARACTERIZATION OF A G-PROTEIN-ACTIVATED HUMAN PHOSPHOINOSITIDE-3 KINASE
    STOYANOV, B
    VOLINIA, S
    HANCK, T
    RUBIO, I
    LOUBTCHENKOV, M
    MALEK, D
    STOYANOVA, S
    VANHAESEBROECK, B
    DHAND, R
    NURNBERG, B
    GIERSCHIK, P
    SEEDORF, K
    HSUAN, JJ
    WATERFIELD, MD
    WETZKER, R
    SCIENCE, 1995, 269 (5224) : 690 - 693
  • [8] Off-label treatment with the selective PI3Kδ inhibitor leniolisib in 2 pediatric patients with activated phosphoinositide 3-kinase delta syndrome 2 (APDS2)
    Neth, Olaf
    Olbrich, Peter
    Gaboli, Mirella
    Manuel Lucena, Jose
    Garcia Garcia, Emilio
    Rodriguez, Alejandro
    Alvarez Del Vayo, Concepcion
    CLINICAL IMMUNOLOGY, 2024, 262
  • [9] ACTIVATED PHOSPHOINOSITIDE 3-KINASE δ SYNDROME
    Nejentsev, Sergey
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (06) : 697 - 697
  • [10] Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence
    Bloomfield, Marketa
    Klocperk, Adam
    Zachova, Radana
    Milota, Tomas
    Kanderova, Veronika
    Sediva, Anna
    FRONTIERS IN PEDIATRICS, 2021, 9
12345